Activating the patient’s immune system
to fight cancer
The 30-month data from the mesothelioma trial was released December 2021. See press release here.
For a video presentation of the 24-month data from June 2021, please see links below:
Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press.
For a company presentation in Norwegian, please see video below.